FDA has granted orphan drug designation to CG'806, a highly potent pan-FLT3/pan-BTK inhibitor, for the treatment of patients with acute myeloid leukemia.
AstraZeneca said the FDA has accepted a supplemental New Drug Application for the use of Tagrisso (osimertinib), a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor with clinical activity against central nervous system metastases, in the 1st-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR mutations (exon 19 deletions or exon 21 (L858R) substitution mutations).
Janssen Biotech Inc. said FDA has granted priority review designation for the New Drug Application for apalutamide, an investigational, next-generation oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer. Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.
Janssen Biotech Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, said that it has entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, subsidiaries of Genscript Biotech Corp., to develop, manufacture and commercialize a chimeric antigen receptor T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen. LCAR-B38M is currently accepted for review by the China Food and Drug Administration and in the planning phase of clinical studies in the United States for multiple myeloma.
Certain head and neck cancers that are positive for high-risk types of human papillomavirus have a better prognosis and may need less aggressive treatment.
The study, “Axicagagene Ciloleucel (CD19 CAR T) in Refractory Large B-Cell Lymphoma,” was led by Sattva Neelapu of the MD Anderson Cancer Center and Frederick Locke of the H. Lee Moffitt Cancer Center and Research Institute.
The cancer death rate dropped 1.7% from 2014 to 2015, continuing a decline that began in 1991 and has reached 26%, resulting in nearly 2.4 million fewer cancer deaths during that time.
Systemic therapies for metastatic renal cell carcinoma (mRCC) have expanded dramatically over the past 3 years.
Howard BurrisLaurie GasparTracey WeisbergTony MokA. William BlackstockLee EllisN. Lynn HenryW. Kimryn RathmellHoward “Skip” Burris III was elected president of the American Society of Clinical Oncology for the term beginning in June 2019.
Howard Hochster assumed the role of associate director for clinical research and chief of gastrointestinal medical oncology at Rutgers Cancer Institute, as well as director of cancer clinical research for oncology services at RWJBarnabas Health.
